The stock of Addex Therapeutics Ltd ADR (NASDAQ: ADXN) has increased by 37.99 when compared to last closing price of 7.66.Despite this, the company has seen a gain of 36.74% in its stock price over the last five trading days. invezz.com reported 2024-08-27 that Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it’s undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.
Is It Worth Investing in Addex Therapeutics Ltd ADR (NASDAQ: ADXN) Right Now?
The 36-month beta value for ADXN is at 1.78. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADXN is 0.82M, and currently, shorts hold a 0.13% of that float. The average trading volume for ADXN on August 27, 2024 was 4.26K shares.
ADXN’s Market Performance
ADXN’s stock has seen a 36.74% increase for the week, with a 32.12% rise in the past month and a 20.11% gain in the past quarter. The volatility ratio for the week is 6.38%, and the volatility levels for the past 30 days are at 5.73% for Addex Therapeutics Ltd ADR The simple moving average for the past 20 days is 36.04% for ADXN’s stock, with a 12.64% simple moving average for the past 200 days.
Analysts’ Opinion of ADXN
Many brokerage firms have already submitted their reports for ADXN stocks, with H.C. Wainwright repeating the rating for ADXN by listing it as a “Buy.” The predicted price for ADXN in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on July 31, 2024 of the current year 2024.
ADXN Trading at 30.89% from the 50-Day Moving Average
After a stumble in the market that brought ADXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.11% of loss for the given period.
Volatility was left at 5.73%, however, over the last 30 days, the volatility rate increased by 6.38%, as shares surge +33.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.00% upper at present.
During the last 5 trading sessions, ADXN rose by +38.55%, which changed the moving average for the period of 200-days by +74.71% in comparison to the 20-day moving average, which settled at $7.90. In addition, Addex Therapeutics Ltd ADR saw 74.71% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ADXN
Current profitability levels for the company are sitting at:
- -6.44 for the present operating margin
- -2.88 for the gross margin
The net margin for Addex Therapeutics Ltd ADR stands at -8.34. The total capital return value is set at 6.56. Equity return is now at value -683.70, with -171.19 for asset returns.
Based on Addex Therapeutics Ltd ADR (ADXN), the company’s capital structure generated -0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -222.43. The debt to equity ratio resting at -0.03. The interest coverage ratio of the stock is -531.96.
Currently, EBITDA for the company is -9.91 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 9.4. The receivables turnover for the company is 5.99for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
In conclusion, Addex Therapeutics Ltd ADR (ADXN) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
